A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
Eligibility criteria
Qualifiers
Chemotherapy-naive participants, planned to receive AC or cisplatin-based chemotherapy greater than or equal to (≥)70 milligrams per square meter (mg/m²), on Day 1 of each cycle, with no multiple administrations during the CINV observation period, from Day 2 to Day 5 of each cycle.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Disqualifiers
Have symptomatic or untreated central nervous system (CNS) metastases.
Have an established diagnosis of uncontrolled diabetes mellitus.
Have a history of, or current evidence of, a clinically significant cardiac condition or QT/QTcF-related conditions.
Have another etiology for nausea and vomiting, or receives medications with know or potential antiemetic activity
Trial design
Treatments tested in this trial
- LY3537021
- Placebo
- Standard of Care Antiemetic Therapies
- Background Chemotherapy
Treatment groups
204 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov